Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech
Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN). The partnership aims to apply advanced robotic technology to cell therapy manufacturing.
Multiply Labs' approach involves robotic systems that can operate various instruments already used in the cell and gene therapy industry, potentially enabling faster adoption of robotic technology. Legend Biotech will evaluate Multiply Labs' robotic technologies and secure priority access to these automated systems.
The collaboration's template is based on a peer-reviewed study published in Cytotherapy, which demonstrated statistical equivalence between manual and automated cell expansion processes. This initiative could lead to reduced labor costs and increased manufacturing throughput in the future.
Multiply Labs, un'azienda di robotica specializzata in sistemi di produzione automatizzati per farmaci personalizzati, ha annunciato una collaborazione con Legend Biotech (NASDAQ: LEGN). L'obiettivo della partnership è applicare tecnologie robotiche avanzate alla produzione di terapie cellulari.
L'approccio di Multiply Labs prevede sistemi robotici in grado di utilizzare vari strumenti già impiegati nell'industria delle terapie cellulari e geniche, potenzialmente accelerando l'adozione della tecnologia robotica. Legend Biotech valuterà le tecnologie robotiche di Multiply Labs e garantirà un accesso prioritario a questi sistemi automatizzati.
Il modello di collaborazione si basa su uno studio sottoposto a revisione paritaria pubblicato su Cytotherapy, che ha dimostrato un'equivalenza statistica tra i processi di espansione cellulare manuali e automatizzati. Questa iniziativa potrebbe portare a una riduzione dei costi del lavoro e a un aumento della capacità produttiva in futuro.
Multiply Labs, una empresa de robótica especializada en sistemas de fabricación automatizados para medicamentos individualizados, ha anunciado una colaboración con Legend Biotech (NASDAQ: LEGN). La asociación tiene como objetivo aplicar tecnología robótica avanzada a la fabricación de terapias celulares.
El enfoque de Multiply Labs implica sistemas robóticos que pueden operar varios instrumentos ya utilizados en la industria de la terapia celular y génica, lo que podría permitir una adopción más rápida de la tecnología robótica. Legend Biotech evaluará las tecnologías robóticas de Multiply Labs y asegurará acceso prioritario a estos sistemas automatizados.
El modelo de colaboración se basa en un estudio revisado por pares publicado en Cytotherapy, que demostró equivalencia estadística entre los procesos de expansión celular manual y automatizado. Esta iniciativa podría conducir a una reducción de costos laborales y un aumento del rendimiento de la fabricación en el futuro.
Multiply Labs는 맞춤형 약물 자동 제조 시스템을 전문으로 하는 로봇 회사로, Legend Biotech (NASDAQ: LEGN)와의 협력을 발표했습니다. 이 파트너십의 목표는 세포 치료 제조에 고급 로봇 기술을 적용하는 것입니다.
Multiply Labs의 접근 방식은 세포 및 유전자 치료 산업에서 이미 사용되는 다양한 기기를 운영할 수 있는 로봇 시스템을 포함하고 있으며, 로봇 기술의 빠른 채택을 가능하게 할 수 있습니다. Legend Biotech는 Multiply Labs의 로봇 기술을 평가하고 이러한 자동화 시스템에 대한 우선 접근을 확보할 것입니다.
이 협력의 모델은 Cytotherapy에 발표된 동료 심사를 거친 연구를 기반으로 하며, 수동 및 자동 세포 확장 과정 간의 통계적 동등성을 입증했습니다. 이 이니셔티브는 향후 노동 비용 절감 및 제조 처리량 증가로 이어질 수 있습니다.
Multiply Labs, une entreprise de robotique spécialisée dans des systèmes de fabrication automatisés pour des médicaments individualisés, a annoncé une collaboration avec Legend Biotech (NASDAQ: LEGN). L’objectif de ce partenariat est d’appliquer une technologie robotique avancée à la fabrication de thérapies cellulaires.
L’approche de Multiply Labs consiste en des systèmes robotiques capables d’utiliser divers instruments déjà employés dans l’industrie de la thérapie cellulaire et génique, ce qui pourrait permettre une adoption plus rapide de la technologie robotique. Legend Biotech évaluera les technologies robotiques de Multiply Labs et obtiendra un accès prioritaire à ces systèmes automatisés.
Le modèle de collaboration est basé sur une étude évaluée par des pairs, publiée dans Cytotherapy, qui a démontré l’équivalence statistique entre les processus d’expansion cellulaire manuels et automatisés. Cette initiative pourrait conduire à une réduction des coûts de main-d'œuvre et à une augmentation des capacités de fabrication à l'avenir.
Multiply Labs, ein Robotikunternehmen, das sich auf automatisierte Fertigungssysteme für individualisierte Medikamente spezialisiert hat, hat eine Zusammenarbeit mit Legend Biotech (NASDAQ: LEGN) angekündigt. Ziel der Partnerschaft ist es, fortschrittliche Robotertechnologie in der Herstellung von Zelltherapien anzuwenden.
Der Ansatz von Multiply Labs umfasst robotergestützte Systeme, die verschiedene Instrumente bedienen können, die bereits in der Zell- und Gentherapiebranche eingesetzt werden, was potenziell eine schnellere Einführung der Robotertechnologie ermöglichen könnte. Legend Biotech wird die Robotertechnologien von Multiply Labs bewerten und sich den priorisierten Zugang zu diesen automatisierten Systemen sichern.
Das Konzept der Zusammenarbeit basiert auf einer von Fachkollegen überprüften Studie, die in Cytotherapy veröffentlicht wurde und die statistische Gleichwertigkeit zwischen manuellen und automatisierten Zellvermehrungsprozessen nachgewiesen hat. Diese Initiative könnte zukünftig zu geringeren Arbeitskosten und einer erhöhten Produktionskapazität führen.
- Collaboration with a global leader in cell therapy (Legend Biotech)
- Potential for faster adoption of robotic technology in cell therapy manufacturing
- Priority access for Legend Biotech to Multiply Labs' automated systems
- Peer-reviewed study supporting the effectiveness of the automated process
- None.
Insights
This collaboration between Multiply Labs and Legend Biotech represents a significant step towards automating cell therapy manufacturing. The use of robotic systems that can operate existing instruments is a novel approach that could accelerate adoption compared to traditional automation methods requiring extensive process changes.
The potential impact on manufacturing efficiency is substantial. By reducing labor costs and potentially increasing throughput, this automation could help address key challenges in cell therapy production, including:
- Scalability issues
- Manufacturing consistency
- Cost reduction
However, it's important to note that the collaboration is still in the evaluation stage. The success and eventual implementation of this technology will depend on the results of Legend Biotech's assessment. While promising, investors should monitor for concrete outcomes and potential timelines for integration into Legend's manufacturing processes.
This partnership highlights Legend Biotech's proactive approach to improving its manufacturing capabilities, which is important in the competitive cell therapy landscape. By securing priority access to Multiply Labs' robotic systems, Legend positions itself at the forefront of manufacturing innovation.
The potential benefits for Legend Biotech include:
- Improved production efficiency
- Reduced manufacturing costs
- Enhanced product consistency
- Increased scalability of cell therapy platforms
These advantages could translate into a stronger market position and improved profitability in the long term. However, investors should consider that implementing new manufacturing technologies often involves significant upfront costs and potential regulatory hurdles. The true value of this collaboration will depend on successful integration and regulatory approval of the automated processes.
The collaboration between Multiply Labs and Legend Biotech will focus on applying advanced robotic technology to the manufacturing of cell therapy platforms
Through this collaboration, Legend Biotech will evaluate Multiply Labs’ robotic technologies, and secure priority access to these automated systems. The template for Multiply Labs’ approach - which will be evaluated through this collaboration - is the peer-reviewed study published earlier this year in Cytotherapy, which showed statistical equivalence between manual and automated cell expansion processes.
“This collaboration enables us to apply our technology in collaboration with some of the best scientists in our field, showcasing the power and potential of our flexible approach to automation and bringing us one step closer to our vision of reducing labor costs and, in the future, boosting manufacturing throughput,” said Fred Parietti, Ph.D., Co-founder and CEO of Multiply Labs. “We look forward to delivering more accessible treatment options to patients.”
ABOUT MULTIPLY LABS
Multiply Labs is a robotics company that provides autonomous manufacturing technology to the pharmaceutical industry. The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space. Multiply Labs’ expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, electrical engineers, computer scientists, software engineers and pharmaceutical scientists. The founding team got in touch because of their shared love of robots at MIT. The company is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240924666477/en/
PRESS CONTACT:
Sonali Tanor
press@multiplylabs.com
Source: Multiply Labs
FAQ
What is the purpose of the collaboration between Multiply Labs and Legend Biotech (LEGN)?
How does Multiply Labs' approach to automation differ from traditional methods?
What evidence supports the effectiveness of Multiply Labs' automated cell expansion process?
What potential benefits does this collaboration offer for Legend Biotech (LEGN)?
